drugset / Trial / NCT01657370
A Pharmacokinetic Study of MK-1602 in the Treatment of Acute Migraine (MK-1602-007)
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study is to characterize the pharmacokinetics of MK-1602 in the treatment of acute migraine, including the influence of demographic and other variables on MK-1602 pharmacokinetics, and to evaluate the relationship between MK-1602 concentrations and efficacy of the drug.
Timeline
- Start
- 2012-08
- Primary completion
- 2012-11
- Completion
- 2012-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MK-1602 | Unknown | 1 mg | Oral |
| Subject | MK-1602 | Unknown | 10 mg | Oral |
| Subject | MK-1602 | Unknown | 25 mg | Oral |
| Subject | MK-1602 | Unknown | 50 mg | Oral |
| Subject | MK-1602 | Unknown | 100 mg | Oral |